Mantle Cell Lymphoma: Updates in the Management of Relapsed/Refractory Disease

Presenter: Mazyar Shadman

Mantle cell lymphoma remains incurable despite recent treatment advances, and most patients experience relapsed/refractory disease. BTK inhibitors are the preferred choice in the relapsed setting, especially in patients with early relapse. For patients with high-risk features such as TP53 mutation, early referral for CAR T-cell therapy should be considered, even in those with stable disease on a BTK inhibitor. Patients without high-risk features may be monitored and initiate CAR T-cell therapy after clinical disease progression. CAR T-cell therapy is an effective treatment with high rate of complete remissions. For patients who do not achieve a complete remission 3 months after CAR-T therapy, bridging therapy with chemotherapy or targeted therapy agents and referral for allogeneic transplant are recommended.

Disclosures: Dr. Shadman has disclosed receiving consulting fees from AbbVie, Inc., Adaptimmune, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Atara Biotherapeutics, BeiGene, Bristol-Myers Squibb Company, Eli Lilly and Company, Epizyme, Genentech, Inc., Innate Pharma, Kite Pharma, MorphoSys AG, Mustang Bio, Pharmacyclics, Sound Biologics, and TG Therapeutics; and receiving grant/research support from AbbVie, Inc., AstraZeneca Pharmaceuticals LP, Atara Biotherapeutics, BeiGene, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Inc., GenMab, Mustang Bio, Pharmacyclics, Sunesis Pharmaceuticals, Inc., and TG Therapeutics.

Correspondence: Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center/University of Washington, 1100 Fairview Avenue North, D5-396, Seattle, WA 98109. Email: mshadman@fredhutch.org
  • 1.

    Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. Version 4.2021. Accessed September 1, 2021. To view the most recent version, visit NCCN.org

    • Search Google Scholar
    • Export Citation
  • 2.

    Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica 2019;104:e211214.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Jain P, Romaguera J, Srour SA, et al. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol 2018;182:404411.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 2018;391:659667.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Wang M, Rule S, Zinzani PL, et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia 2019;33:27622766.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Song Y, Zhou K, Zou D, et al. ZANUBRUTINIB (zanu) in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL): long-term efficacy and safety results from a phase 2 study [abstract]. Presented at the European Hematology Association 2021 Virtual Congress; June 9–17, 2021. Abstract EP789.

    • Search Google Scholar
    • Export Citation
  • 7.

    Kaptein A, de Bruin G, Emmelot-van Hoek M, et al. Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies [abstract]. Blood 2018;132(Suppl 1):Abstract 1871.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Kumar A, Sha F, Toure A, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J 2019;9:50.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Visco C, Di Rocco A, Evangelista A, et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia 2021;35:787795.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012;13:716723.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:48674874.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Lamm W, Kaufmann H, Raderer M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 2011;96:10081014.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    McCulloch R, Visco C, Eyre TA, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol 2020;189:684688.

  • 14.

    Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020;382:13311342.

  • 15.

    Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet 2021;397:892901.

  • 16.

    Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med 2018;378:12111223.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 335 335 335
PDF Downloads 159 159 159
EPUB Downloads 0 0 0